Physician profile
Peter J Hynes
NPI 1497953210
$12,200.77
in general payments reported to CMS, 2019-2025
38 companies · $6,133 in 2025
The $6,133 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $903 · 2021: $1,245 · 2022: $878 · 2023: $1,207 · 2024: $416 · 2025: $6,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,376 · Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,376.35 |
| Food and Beverage | $2,379.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $5,376.35 | 2025 | Definity |
| Astrazeneca Pharmaceuticals LP | $1,067.23 | 2019-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $987.03 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $891.23 | 2019-2025 | |
| Abbott Laboratories | $582.66 | 2021-2025 | Aveir, Mitraclip, Cardiomems |
| Actelion Pharmaceuticals US, INC. | $500.72 | 2019-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $386.14 | 2019-2025 | Avvigo Guidance System |
| E.R. Squibb & Sons, L.L.C. | $306.48 | 2019-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.75 | 2019-2024 | Jardiance |
| Amgen INC. | $239.86 | 2019-2023 | Repatha |
| Abiomed | $211.34 | 2019-2023 | Impella |
| Amarin Pharma, INC. | $197.72 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $167.11 | 2019-2024 | |
| Pfizer INC. | $145.83 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.31 | 2019-2023 | Lifevest |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.